Project Grant R01AI189290
Award Date
7/7/25
Completion Date
6/30/30
Dollars Obligated
$355K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
This $537,619 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel electrochemical biosensor technology capable of simultaneously detecting HIV, hepatitis B, and hepatitis C viruses. The project aims to integrate the recently developed four-way junction (4WJ) electrochemical biosensor with an isothermal nucleic acid amplification technique to create a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University a $2,082,247 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an economical, rapid molecular diagnostic system for detecting hepatitis C virus (HCV) and HIV from whole blood samples. The research aims to overcome barriers to low-cost implementation of molecular diagnostics for RNA viruses by creating novel chemistries and microfluidics to enable minimally...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $884,453 Project Grant to Brigham & Women's Hospital Inc. to develop a rapid, cost-effective point-of-care (POC) diagnostic test for Hepatitis C Virus (HCV) detection. The 5-year project, which commenced on November 22, 2024, aims to create a highly sensitive and specific HCV antigen (Ag) testing solution that can streamline...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University a $673,158 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a proteomics atlas of HIV/HBV co-infections for advancing HBV cure strategies. The project aims to use robust co-culture systems, CRISPR screens, and multi-omics approaches in primary human hepatocytes and CD4+ T cells to discover and validate host factors and antivirals against HIV/HBV...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $272,133 to Rutgers, The State University of New Jersey to develop a low-cost, instrument-free rapid antigen test for the diagnosis of active hepatitis C virus (HCV) infection. The goal is to create a point-of-care diagnostic that can accelerate the identification of individuals with active HCV infection and link...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $647,533 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Connecticut Health Center (UCHC) to develop a rapid, affordable, and sensitive CRISPR cascade signal amplification approach for HIV viral load testing in clinical samples. The project aims to investigate the allosteric regulation mechanism of CRISPR activation by HIV RNA and create a CRISPR cascade signal amplification...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Project Grant to Electronic Biosciences, Inc. to develop a novel point-of-care technology for monitoring immunosuppressant drug levels. The key product being developed is a portable, fingerstick-based testing system that can provide convenient and frequent immunosuppressant drug level measurements. This will enable more precise dosing for...
This federal Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, provides $592,027 to Northwestern University to develop and validate a point-of-care molecular diagnostic test for active hepatitis C virus (HCV) infection. The project aims to create a portable, low-cost device that can rapidly diagnose active HCV by detecting viral RNA, eliminating the need for two-step serologic and laboratory-based...